Abstract | BACKGROUND: Patients with liver cirrhosis are recommended ultrasonography screening for early detection of hepatocellular carcinoma to increase the chances of curative treatment. However, ultrasonography alone lacks in sensitivity. Adding plasma biomarkers may increase the detection rate. We performed a broad exploratory analysis to find new plasma proteins with potential applicability for HCC screening in patients with cirrhosis. METHODS: In a protein discovery cohort of 172 patients with cirrhosis or HCC, we screened for 481 proteins with suspension bead array or proximity extension assay. From these, 24 proteins were selected for further analysis in a protein verification cohort (n = 160), using ELISA, Luminex or an electrochemiluminescence platform. A cut-off model and a stepwise logistic regression model were used to find combinations of proteins with the best discriminatory performance between HCC and cirrhosis. RESULTS: CONCLUSION: In the present study, TXNRD1 improves the sensitivity and specificity of AFP and DCP as HCC screening tools in patients with cirrhosis. We suggest that TXNRD1 should be validated in prospective settings as a new complementary HCC biomarker together with AFP and DCP.
|
Authors | Robin Zenlander, Claudia Fredolini, Jochen M Schwenk, Ingvar Rydén, Peter Påhlsson, Christian Löwbeer, Gösta Eggertsen, Per Stål |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
2023 Jul-Dec
Vol. 58
Issue 9
Pg. 998-1008
ISSN: 1502-7708 [Electronic] England |
PMID | 37017178
(Publication Type: Journal Article)
|
Chemical References |
- alpha-Fetoproteins
- Biomarkers
- Biomarkers, Tumor
- Protein Precursors
- Prothrombin
- Thioredoxin Reductase 1
|
Topics |
- Humans
- alpha-Fetoproteins
(analysis)
- Biomarkers
- Biomarkers, Tumor
- Carcinoma, Hepatocellular
(diagnostic imaging)
- Liver Cirrhosis
(diagnosis)
- Liver Neoplasms
(diagnostic imaging)
- Prospective Studies
- Protein Precursors
- Prothrombin
- Sensitivity and Specificity
- Thioredoxin Reductase 1
|